Randomized trial shows gabapentin and solifenacin enhance symptom control in patients with ureteral stents, indicating better health outcomes.
Key Points
To evaluate the effectiveness of gabapentin combined with solifenacin for managing symptoms after double-J stent placement.
Randomized controlled trial conducted at a tertiary referral center.
160 adult patients undergoing ureteroscopic lithotripsy with double-J stent placement were randomized into two groups.
Intervention group received gabapentin 100 mg and solifenacin 5 mg daily for 2 weeks; control group received solifenacin plus placebo.
The intervention group had a mean total Ureteral Stent Symptom Questionnaire score of 75.17, significantly lower than the control group's score of 87.98 (P < 0.001).
Significant improvements were seen in urinary symptoms, pain, general health, work performance, with P < 0.05 for all.